The antibodies market is estimated to be valued at US$ 224,083.5 Mn or Mn in 2023 and is expected to exhibit a CAGR of 12.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

 

Market Overview:

Antibodies are Y-shaped proteins that are produced by B-cells in the immune system. They play a key role in identifying and neutralizing foreign objects like bacteria and viruses. In the pharmaceutical industry, antibodies are used for several applications such as diagnostic tests, cancer treatment, and autoimmune disease management. Monoclonal antibodies targeting specific proteins or antigens have revolutionized the treatment landscape for diseases like rheumatoid arthritis, multiple sclerosis, and cancer.

 

Market Dynamics:

The increasing prevalence of chronic diseases and growth in the biologics market are some of the major drivers of the antibodies market. According to the Centers for Disease Control and Prevention, around 6 in 10 Americans live with at least one chronic disease such as heart disease, cancer, or diabetes. Biologics have emerged as an important treatment avenue for diseases which do not respond well to small-molecule drugs. The rising demand for targeted therapies and the ability of antibodies to treat complex diseases are augmenting the demand in the market. Moreover, continuous advancements in antibody engineering technologies to produce novel antibodies with improved safety profiles is also supporting market growth.
 

Segment Analysis

The antibodies market can be segmented by product into monoclonal antibodies, polyclonal antibodies, antibody drug conjugates, and others. Among these, the monoclonal antibodies segment dominated the market in 2022 and is expected to continue its dominance during the forecast period. Monoclonal antibodies have high specificity and affinity for its specific antigen. It has minimal side effects and is widely used for treating various conditions like cancer, infectious diseases, and inflammatory diseases.

 

PEST Analysis

Political: Governments across the globe are supporting research and development activities in the life sciences sector by providing funds. Various regulatory policies are also framed to expedite the review and approval process of novel antibodies with high therapeutic potential.
Economic: The rising incidence of chronic and infectious diseases is driving the demand for antibodies globally. However, high capital investment requirements for developing novel antibodies may restrain market growth to some extent.
Social: Growing awareness about advantages of targeted therapy and rising healthcare expenditure are supporting the adoption of antibody drugs. Social media is also playing a role in enhancing knowledge about various antibodies available in the market.
Technological: Advancements in hybridoma technology and genetic engineering have enabled development of better humanized antibodies with high affinity and specificity. Automation and use of robotics in manufacturing have further improved process efficiency and scaled up production.

 

Key Takeaways

The Global Antibodies Market Growth is expected to witness high, exhibiting CAGR of 12.% over the forecast period, due to increasing incidence of chronic diseases and rising demand for monoclonal antibody therapeutics. The market size for 2023 is estimated to be US$ 224,083.5 Mn.

Regionally, North America captures over 40% share of the global antibodies market and is expected to maintain its dominance during the forecast period. This can be attributed to the presence of major players, rising healthcare spending, and high adoption of novel antibody drugs within the region.

Key players operating in the antibodies market are Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd. The market is highly fragmented with the top 3 players accounting for less than 30% share. Companies are focused on developing advanced antibody therapies for various therapeutic areas.

Read More - https://www.newsanalyticspro.com/antibodies-market-share-growth-analysis-demand-and-size-forecast/